scholarly journals Retrospective analysis of pediatric hepatoblastoma with tumor rupture: experience from a single center

2021 ◽  
Author(s):  
Yu-Tong Zhang ◽  
Yu-fei Zhao ◽  
Dian-fei Yang ◽  
Jian Chang
Keyword(s):  
High Risk ◽  
Poor Prognosis ◽  
Risk Group ◽  
Interleukin 2 ◽  
Complete Response ◽  
High Risk Group ◽  
Free Fluid ◽  
Tumor Rupture ◽  
High Risk Factor ◽  
Peritoneal Perfusion

Abstract Background Hepatoblastoma (HB) tumor rupture is currently considered as a high-risk factor in some risk-stratification systems. This study aimed to investigate the value of HB tumor rupture in predicting the poor prognosis of child patients. Methods The clinical data from children with high-risk HB or HB tumor rupture at our institution from October 2008 to October 2017 were retrospectively reviewed and analyzed. Results Altogether 34 children with high-risk HB or HB tumor rupture were retrospected, including 25 in the high-risk group and 9 in tumor rupture group. The 3-year overall survival (OS) rate in tumor rupture group was significantly higher than that in high-risk group (100% vs 60%, p=0.035). In tumor rupture group, 7 (77.8%) out of 9 patients had the hemoglobin level ≤ 8 g/L and 3 (33.3%) had that ≤ 6 g/L at the time of diagnosis. Peritoneal perfusion with normal saline and interleukin-2 was implemented for each patient until the free fluid was under normal level. At the end of the treatment, 7 (77.8%) of 9 patients achieved complete response (CR). No patient died at the last follow-up. Conclusions Tumor rupture is not predictive of poor prognosis with the risk of peritoneal dissemination/relapse.

scholarly journals Chemo-resistant gestational trophoblastic neoplasia: a review of cases at a tertiary cancer centre

2019 ◽  
Vol 8 (4) ◽  
pp. 1620
Author(s):  
Sharayu R. Mirji ◽  
Shilpa M. Patel ◽  
Ruchi S. Arora ◽  
Ava D. Desai ◽  
Meeta H. Mankad ◽  
...  
Keyword(s):  
High Risk ◽  
Risk Group ◽  
Complete Response ◽  
High Risk Group ◽  
Low Risk ◽  
Gestational Trophoblastic Neoplasia ◽  
First Line ◽  
Β Hcg ◽  
Cure Rates ◽  
Line Chemotherapy

Background: Gestational trophoblastic neoplasia (GTN) was earlier a dreaded malignancy with high mortality rates. GTN is now considered to be one of the most curable solid tumours in women with cure rates greater than 90% even in the presence of metastases. Despite the high chemo sensitivity, treatment failure or drug resistance has been described in both groups.Methods: In this study, available records of GTN cases over 6 years were reviewed with emphasis on those who were resistant to the first line of chemotherapy. Of these, 37(34.58%) were resistant to the first line of chemotherapy. These cases were studied with respect to age, parity, antecedent pregnancy, interval from antecedent pregnancy, pretreatment β hCG, risk score and presence of metastases. The data was analyzed in order to find any risk factors associated with chemo-resistance.Results: Total number of cases of GTN was 107. Out of these 107 cases, 63 (58.88%) were low risk and 44 (41.12%) were high risk according to FIGO scoring system. Complete response was achieved with first line chemotherapy in 70 (65.42%) patients. The remaining 37 (34.57%) were resistant to first line chemotherapy. In the low risk group, 30 (47.62%) cases, and in the high-risk group, 7(15.91%) were resistant to first line of chemotherapy.Conclusions: Despite the high chemo sensitivity of GTN, resistance to first line chemotherapy may be encountered in up to 40% of cases.  It is important to identify the patients who are at risk to develop resistance, early identification of resistance and change of chemotherapy so as to minimize the exposure of these patients to ineffective chemotherapy.

15-year survival after radical prostatectomy (RP): Which prognostic factors are available for patient counseling?

2013 ◽  
Vol 31 (6_suppl) ◽  
pp. 181-181
Author(s):  
Sophie D. Fossa ◽  
Haakon Waehre ◽  
Milada Cvancarova ◽  
Haavard E Danielsen
Keyword(s):  
Prostate Cancer ◽  
Prognostic Factors ◽  
High Risk ◽  
Poor Prognosis ◽  
Risk Group ◽  
Rare Event ◽  
Observation Time ◽  
High Risk Group ◽  
Patient Counseling ◽  
Psa Relapse

181 Background: Studies on 15-year Post-RP survival including data on PSA relapse (PSA-Rel) are rare. We established the 15-year post-RP prostate cancer specific mortality (PCSM), to explore the time to PSA-Rel and PCSM thereafter, and to identify clinically available prognostic factors. Methods: In men prostatectomized from 1987-2004 slightly modified D`Amico risk groups were identified (T1: No palpable tumor ;”T2 unilateral”/”T2 bilateral” according to tumor palpability in one or both lobes). PSA –Rel was defined as PSA ≥4 µg/l before 2000, and thereafter as PSA >0.2 µg/l. Delay of RP was defined as RP performance 3-12 months after diagnosis. Competing risk modeling was performed with a significance level of <0.05. Results: After a median observation time of 12 years (range: 0-22), of 309 men (median age:62 years [range:40-74]) 40 have died from prostate cancer ( PCa) and 68 due to other causes (15-year PCSM: 15% [95%CI: 10-19%). No difference of PCSM was found between the low (N: 12) and the intermediate group (N: 121), the “conventional” high risk group ( N: 121) displaying a 24% PCSM rate (95% CI:16-32%) with particularly poor prognosis for men who presented with two high risk factors ( N. 32 ; PCSM: 33% [95% CI:20-46%]). The median time to PSA relapse (N: 152) was 5 years (range: 0-17), the median overall survival time after PSA- Rel being 7 years (range: 0-17). PCSM continued to increase after 10 years. Delay of RP had no impact on PCSM. Conclusions: After a median observation time of 12 years approximately 1 of 7 men with localized PCa, most of them diagnosed before the PSA- era, have died of prostate cancer. The “conventional” high-risk group is prognostically heterogeneous: Men with two high risk criteria have a particularly poor prognosis. PSA-Rel 10 years after RP is no rare event followed by survival times of >10 years. Delay of RP for up to one year had no impact on PCSM.

scholarly journals A Risk Signature Established From Three Coagulation-fibrinolysis Genes Predicts Prognosis in Digestive System Pancancer

2022 ◽  
Author(s):  
Xingyun Wang ◽  
Jinli Ji ◽  
Ying Jiang ◽  
Yiyang Zhao ◽  
Zheyao Song ◽  
...  
Keyword(s):  
High Risk ◽  
Poor Prognosis ◽  
Digestive System ◽  
Risk Group ◽  
Epigenetic Modification ◽  
Enrichment Analysis ◽  
Risk Groups ◽  
High Risk Group ◽  
Gene Set Enrichment Analysis ◽  
Cox Analysis

Abstract Venous thromboembolism (VTE) is one of the major complications of digestive system cancer, and coagulation-fibrinolysis genes play an important role in VTE. We used univariate Cox analysis, least absolute shrinkage and selection operator (LASSO), and multivariate Cox analysis to construct 3-PCFGs (prognostic coagulation-fibrinolysis genes) model based on six prognostic coagulation-fibrinolysis genes. Gene set enrichment analysis (GSEA) was used to analyze the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways of the high- and low-risk groups. In addition, we classified digestive system pancancer patients into three clusters A, B, and C based on 3-PCFGs by K means. High-risk group and cluster C were associated with poor prognosis in digestive system pancancer. The m6A-related genes ALKBH5, FTO, RBM15, YTHDC1, and YTHDC2 (P<0.001) were highly expressed in the high-risk group and cluster C. The risk score was positively correlated with cancer-associated fibroblasts and endothelial cells. Cluster C had the highest immune score and stromal score. The poor prognosis in the high-risk group and cluster C may be affected by m6A epigenetic modification and immune microenvironment components in the digestive system pancancer.

scholarly journals Multi-Omics Profiling Identifies Risk Hypoxia-Related Signatures for Ovarian Cancer Prognosis

2021 ◽  
Vol 12 ◽  
Author(s):  
Xingyu Chen ◽  
Hua Lan ◽  
Dong He ◽  
Runshi Xu ◽  
Yao Zhang ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
High Risk ◽  
Poor Prognosis ◽  
Cox Regression ◽  
Risk Group ◽  
High Risk Group ◽  
Low Risk ◽  
Cancer Prognosis ◽  
High Risk Patients ◽  
Risk Patients

BackgroundOvarian cancer (OC) has the highest mortality rate among gynecologic malignancy. Hypoxia is a driver of the malignant progression in OC, which results in poor prognosis. We herein aimed to develop a validated model that was based on the hypoxia genes to systematically evaluate its prognosis in tumor immune microenvironment (TIM).ResultsWe identified 395 hypoxia-immune genes using weighted gene co-expression network analysis (WGCNA). We then established a nine hypoxia-related genes risk model using least absolute shrinkage and selection operator (LASSO) Cox regression, which efficiently distinguished high-risk patients from low-risk ones. We found that high-risk patients were significantly related to poor prognosis. The high-risk group showed unique immunosuppressive microenvironment, lower antigen presentation, and higher levels of inhibitory cytokines. There were also significant differences in somatic copy number alterations (SCNAs) and mutations between the high- and low-risk groups, indicating immune escape in the high-risk group. Tumor immune dysfunction and exclusion (TIDE) and SubMap algorithms showed that low-risk patients are significantly responsive to programmed cell death protein-1 (PD-1) inhibitors.ConclusionsIn this study, we highlighted the clinical significance of hypoxia in OC and established a hypoxia-related model for predicting prognosis and providing potential immunotherapy strategies.

scholarly journals Ibrutinib Plus Fludarabine, Cyclophosphamide, and Rituximab As the Treatment for Chronic Lymphocytic Leukemia/ Small Lymphocytic Leukemia: A Single-Center Real World Study

Blood ◽  
2020 ◽  
Vol 136 (Supplement 1) ◽  
pp. 29-30
Author(s):  
Huayuan Zhu ◽  
Hui Shen ◽  
Yilian Yang ◽  
Chong-Yang Ding ◽  
Yeqin Sha ◽  
...  
Keyword(s):  
High Risk ◽  
Chronic Lymphocytic Leukemia ◽  
Interim Analysis ◽  
Response Rate ◽  
Risk Group ◽  
Complete Response ◽  
High Risk Group ◽  
Lymphocytic Leukemia ◽  
Occurrence Rate ◽  
Hematological Toxicity

Purpose: To evaluate the safety and efficacy of ibrutinib plus fludarabine, cyclophosphamide, and rituximab (iFCR) as the treatment for chronic lymphocytic leukemia (CLL)/ small lymphocytic leukemia (SLL) patients, we conducted time-limited, minimal residual disease (MRD)-driven real world study in The First Affiliated Hospital of Nanjing Medical University Methods: We enrolled patients aged 18 to 65 years old with CLL/SLL who required treatment. Oral Ibrutinib was given continuously (420 mg/day) from day 0, and patients were administered intravenously rituximab (375mg/m2 in day 0 of cycle 1; 500mg/m2 in day 0 of cycle 2-3), fludarabine (25mg/m2, days 1-3) and cyclophosphamide (250mg/m2, days 1-3), every 28-day cycles. All the patients received 3 cycles of iFCR in the first stage. Interim analysis was done according to the 2018 iwCLL criteria and MRD was detected by flow cytometry. Patients who achieved complete response (CR) or partial response (PR) with low MRD level (L-MRD, 10-4-10-2) or undetectable MRD (uMRD) level (&lt;10-4) in peripheral blood (PB) were given 3 times of rituximab or the 4th cycle of iFCR, and then turned to ibrutinib maintenance. Patients who achieved PR with high MRD level (&gt;10-2) in PB or bone marrow (BM), or with diameter of residual lymph node larger than 3cm were administered another 3 cycles of iFCR (6 in all) and followed by ibrutinib maintenance. The primary endpoint was the proportion of patients who achieved uMRD in the PB after 3 cycles of iFCR. The secondary endpoint was overall response rate (ORR), complete response rate (CR) and the number of adverse events (AE). Results: Between May 2019 and June 2020, 29 CLL/SLL patients were enrolled in this cohort with 27 CLL and 2 SLL. 26 of patients were the previously untreated and 3 of patients were relapse or treated before. The median age of patients was 53 years old. Unmutated IGHV was detected in 14 (50.0%) of 29 patients, 4 patients had del(17p) and/or TP53 mutation (13.8%), 7 patients had del(11q) (24.1%), 7 had NOTCH1 mutation (24.1%) and 7 had MYD88 mutation (24.1%). 8 patients (30.8%) were classified as low-risk group according to CLL-IPI, with 9 in intermediate-risk group (34.6%), 5 in high-risk group (19.2%) and 4 in very-high risk group (15.4%). At data cutoff (1st July, 2020), the median follow-up and treatment time was seven months (1-13 months) with 23 patients had completed at least two cycles of iFCR. At interim analysis, the ORR was 100% with 8 patients achieved CR (34.8%), 3 achieved CRi (13.0%) and 12 achieved PR (52.2%). 57.1% (12/21) achieved uMRD in both PB and BM, among which 6 of them (28.6%) achieved CR/CRi and 6 achieved PR (28.6%). All four patients with TP53 abnormalities achieved PR and two of them (50.0%) achieved uMRD in both PB and BM. One of 6 patients with del(11q) achieved CR (16.7%) and five achieved PR (83.3%), with 2 achieved uMRD in both PB and BM (33.3%). Among 13 assessable patients with unmutated IGHV, four of them achieved CR (30.8%) and nine achieved PR (69.2%), with 5 achieved uMRD in both PB and BM (38.5%). 18 patients had turned to ibrutinib maintenance with 12 of them finished 4th cycle of iFCR or 3 additional cycles of rituximab and could be assessed further. 10 of the patients achieved CR/CRi (83.3%) and 2 achieved PR (16.7%), with 8 achieved uMRD in both PB and BM (66.7%). The most common hematological toxicity events were neutropenia and thrombocytopenia and the non-hematological toxicity events were nausea and vomiting. The occurrence rate of grade 3 to 4 neutropenia and agranulocytic fever were 51.9% (15/29) and 17.2% (5/29) respectively. The most common ibrutinib-related AE were purpura, rash and diarrhea. The occurrence rate of AE induced discontinued ibrutinib more than 7 days, discontinued ibrutinib fewer than 7 days and ibrutinib decrement were 20.7%(6/29), 17.2%(5/29) and 20.7%(6/29) respectively. Conclusion: MRD-driven Ibrutinib plus FCR could achieve high response rate with uMRD in yonger fit patients with CLL/SLL, with manageable toxicity. Ibrutinib plus FCR could be one of the most promising choice as a time-limited regimen in the new drug era. Disclosures No relevant conflicts of interest to declare.

scholarly journals Identification of a Novel Signature Predicting Overall Survival in Head and Neck Squamous Cell Carcinoma

2021 ◽  
Vol 8 ◽  
Author(s):  
Haige Zheng ◽  
Huixian Liu ◽  
Yumin Lu ◽  
Hengguo Li
Keyword(s):  
Overall Survival ◽  
Squamous Cell Carcinoma ◽  
Regression Analysis ◽  
High Risk ◽  
Cell Carcinoma ◽  
Poor Prognosis ◽  
Cox Regression ◽  
Risk Group ◽  
High Risk Group ◽  
Cox Regression Analysis

Background: Head and neck squamous cell carcinoma (HNSCC) is a highly heterogeneous tumor with a high incidence and poor prognosis. Therefore, effective predictive models are needed to evaluate patient outcomes and optimize treatment.Methods: Robust Rank Aggregation (RRA) method was used to identify highly robust differentially-expressed genes (DEGs) between HNSCC and normal tissue in 9 GEO and TCGA datasets. Univariate Cox regression analysis and Lasso Cox regression analysis were performed to identify DEGs related to the Overall survival (OS) and to construct a prognostic gene signature (HNSCCSig). External validation was performed using GSE65858 dataset. Moreover, comprehensive bioinformatics analyses were used to identify the association between HNSCCSig and tumor immune environment.Results: A total of 257 reliable DEGs were identified by differentially analysis result of TCGA and GSE65858 datasets. The HNSCCSig including 7 mRNAs (SLURP1, SCARA5, CLDN10, MYH11, CXCL13, HLF, and ITGA3) were developed and validated to identify high-risk group who had a worse OS than low-risk group in TCGA and GSE65858 datasets. Cox regression analysis showed that the HNSCCSig could independently predict OS in both the TCGA and the GSE65858 datasets. Further research demonstrated that the infiltration bundance of CD8 + T cells, B cells, neutrophils, and NK cells were significantly lower in the high-risk group. A nomogram was also constructed by combining the HNSCCSig and clinical characters.Conclusion: We established and validated the HNSCCSig consisting of SLURP1, SCARA5, CLDN10, MYH11, CXCL13, HLF, and ITGA3. A nomogram combining HNSCCSig and some clinical parameters was constructed to identify high-risk HNSCC-patients with poor prognosis.

scholarly journals Integrative analysis and experiments to explore angiogenesis regulators correlated with poor prognosis, immune infiltration and cancer progression in lung adenocarcinoma

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Songhua Cai ◽  
Xiaotong Guo ◽  
Chujian Huang ◽  
Youjun Deng ◽  
Longde Du ◽  
...  
Keyword(s):  
High Risk ◽  
Lung Adenocarcinoma ◽  
Cancer Progression ◽  
Poor Prognosis ◽  
Risk Group ◽  
Critical Role ◽  
Differential Expression Analysis ◽  
High Risk Group ◽  
Prognostic Models ◽  
Immune Infiltration

AbstractAngiogenesis is the process of capillary sprouting from pre-existing vessels and it plays a critical role in the carcinogenic process of lung adenocarcinoma (LUAD). However, the association of angiogenesis regulators with the prognosis and progression of LUAD needs to be further elucidated. In this study, we adopted differential expression analysis, Cox proportional hazards (PH) regression analysis and experimental validation to identify angiogenesis regulators correlated with a poor prognosis, immune infiltration and cancer progression in LUAD. These results showed that the diagnostic and prognostic models based on COL5A2 and EPHB2 served as independent biomarkers with superior predictive ability. The patients in the high-risk group exhibited a worse prognosis in the TCGA cohort (P < 0.001, HR = 1.72, 95% CI 1.28–2.30), GSE310210 cohort (P = 0.005, HR = 2.87, 95% CI 1.46–5.61), and GSE31019 cohort (P = 0.01, HR = 2.14, 95% CI 1.19–3.86) than patients in the low-risk group. The high prognostic risk patients had a higher TMB (P < 0.001); higher fractions of M0 macrophages, neutrophils, NK cells resting, and T cells CD4 memory activated (P < 0.05); and higher expression of immune checkpoints PD-1, PDL-1, PDL-2, and B7H3 (P < 0.001). Patients in the high-risk group were more sensitive to chemotherapeutic drugs and molecular targeted drugs such as cisplatin, doxorubicin, gefitinib, and bosutinib (P < 0.0001). In addition, inhibition of COL5A2 and EPHB2 effectively suppressed the proliferation and migration of LUAD cells. The current study identified angiogenesis regulators as potential biomarkers and therapeutic targets for LUAD and may help to further optimize cancer therapy.

scholarly journals Signatures of Multi-Omics Reveal Distinct Tumor Immune Microenvironment Contributing to Immunotherapy in Lung Adenocarcinoma

2021 ◽  
Vol 12 ◽  
Author(s):  
Ziqi Huang ◽  
Baihui Li ◽  
Yan Guo ◽  
Lei Wu ◽  
Fan Kou ◽  
...  
Keyword(s):  
T Cells ◽  
High Risk ◽  
Cd8 T Cells ◽  
Poor Prognosis ◽  
Molecular Subtypes ◽  
Risk Group ◽  
High Risk Group ◽  
Omics Data ◽  
Immune Microenvironment ◽  
Tumor Immune Microenvironment

BackgroundLung adenocarcinoma (LUAD) contains a variety of genomic and epigenomic abnormalities; the effective tumor markers related to these abnormalities need to be further explored.MethodsClustering analysis was performed based on DNA methylation (MET), DNA copy number variation (CNV), and mRNA expression data, and the differences in survival and tumor immune microenvironment (TIME) between subtypes were compared. Further, we evaluated the signatures in terms of both prognostic value and immunological characteristics.ResultsThere was a positive correlation between MET and CNV in LUAD. Integrative analysis of multi-omics data from 443 samples determined molecular subtypes, iC1 and iC2. The fractions of CD8+ T cells and activated CD4+ T cells were higher, the fraction of Tregs was lower, and the expression level of programmed death-ligand 1 (PD-L1) was higher in iC2 with a poor prognosis showing a higher TIDE score. We selected PTTG1, SLC2A1, and FAM83A as signatures of molecular subtypes to build a prognostic risk model and divided patients into high-risk group and low-risk group representing poor prognosis and good prognosis, respectively, which were validated in 180 patients with LUAD. Further, the low-risk group with lower TIDE score had more infiltrating immune cells. In 100 patients with LUAD, the high-risk group with an immunosuppressive state had a higher expression of PD-L1 and lower counts of CD8+ T cells and dendritic cells.ConclusionsThese findings demonstrated that combined multi-omics data could determine molecular subtypes with significant differences of prognosis and TIME in LUAD and suggested potent utility of the signatures to guide immunotherapy.

scholarly journals Sinonasal Mucormycosis: A Series of Seven Cases

2012 ◽  
Vol 5 (1) ◽  
pp. 25-27 ◽  
Author(s):  
S Vinaya Babu ◽  
U Venkatesh ◽  
Thomas Prasannaraj ◽  
KV Shivaprakash ◽  
S Prathima
Keyword(s):  
High Risk ◽  
Poor Prognosis ◽  
South India ◽  
Preventive Measures ◽  
Risk Group ◽  
Agricultural Practices ◽  
Face Mask ◽  
High Risk Group ◽  
Present Series ◽  
Agricultural Activities

ABSTRACT Mucormycosis is the disease caused by the fungus of the order mucorales. Rhizopus species are the most common causative organisms. It is often associated with compromised immunity and poor prognosis. Farmers constitute the high risk group and peak incidence is observed during the monsoons which correspond to the agricultural practices in South India. Preventive measures such as the use of a face mask during agricultural activities may decrease the risk of acquiring this debilitating illness. We present series of seven cases of sinonasal mucormycosis. How to cite this article Babu SV, Venkatesh U, Prasannaraj T, Shivaprakash KV, Prathima S. Sinonasal Mucormycosis: A Series of Seven Cases. Clin Rhinol Int J 2012;5(1):25-27.

Nhận xét đặc điểm lâm sàng, cận lâm sàng và kết quả hóa trị bệnh u lá nuôi thời kỳ thai nghén tại Bệnh viện K

2022 ◽  
Author(s):  
Thanh Binh Han-Thi
Keyword(s):  
High Risk ◽  
Actinomycin D ◽  
Risk Group ◽  
Complete Response ◽  
High Risk Group ◽  
Low Risk ◽  
Gestational Trophoblastic Neoplasia ◽  
Old Patients ◽  
Beta Hcg ◽  
Leucovorin Calcium

TÓM TẮT Mục tiêu: Nhận xét một số đặc điểm lâm sàng, cận lâm sàng và kết quả hóa trị bệnh u lá nuôi thời kỳ thai nghén. Phương pháp: Nghiên cứu mô tả hồi cứu kết hợp tiến cứu. 36 bệnh nhân nữ được chẩn đoán xác định là u lá nuôi thời kỳ thai nghén từ tháng 01/2015 đến 10/2020, được phân loại thành nhóm nguy cơ thấp và cao. Nhóm nguy cơ thấp được điều trị bằng Methotrexate đơn trị. Nhóm nguy cơ cao được điều trị phác đồ EMA/CO (etoposide, methotrexate, actinomycin D/leucovorin calcium, vincristine, cyclophosphamide). Kết quả: Tuổi hay gặp nhất là > 40 tuổi. Số bệnh nhân vào viện vì ra máu âm đạo chiếm cao nhất 52,8%. Đa số bệnh nhân có Beta - HCG ban đầu < 100000 chiếm 83,3%. Thể mô bệnh học hay gặp nhất là ung thư nhau thai với 50%. Tổn thương di căn phổi chiếm cao nhất 53,8%. Tỷ lệ bệnh nhân có nguy cơ thấp và cao là như nhau chiếm 50%. Phác đồ Methotrexate đơn thuần: đáp ứng hoàn toàn là 83,3%. Phác đồ EMA/CO: tỷ lệ đáp ứng chung là 83,3%. Tỷ lệ bệnh nhân có độc tính độ 3,4 chiếm tỷ lệ nhỏ, chủ yếu trên huyết học. Kết luận: Các phác đồ cho kết quả tốt, tỷ lệ đáp ứng cao và an toàn. ABSTRACT REMARKS ON CHARACTERISTICS OF CLINICAL, SUBCLINICAL, AND RESULTS OF CHEMOTHERAPY ON GESTATIONAL TROPHOBLASTIC NEOPLASIA PATIENTS IN K HOSPITAL Objective: To remark characteristics of clinical, subclinical, and results of chemotherapy on gestational trophoblastic neoplasia patients. Methods: A retrospective combined prospective study was conducted on 36 women with low and high risks of gestational trophoblastic neoplasia from January 2015 to October 2020. The low - risk group was treated with methotrexate alone. The high - risk group was treated with EMA/CO (etoposide, methotrexate, actinomycin D/ leucovorin calcium, vincristine, cyclophosphamide). Results: The most common age was > 40 years old. Patients admitted to the hospital because of vaginal bleeding accounted for the highest rate of 52.8%. Most of the patients (83.3%) had initial Beta - HCG < 100000. The most common histopathological form is choriocarcinoma, with 50%. Lung metastatic lesions accounted for the highest (53.8%). The proportion of low - risk and high - risk patients was about 50%. The complete response rate was 83,3% with the methotrexate regimen and was 83,3% with EMA/CO regimen. The proportion of patients with grade 3.4 toxicity accounted for a small proportion, mainly in hematology. Conclusion: The regimens had good results, high response rates, and safety. Keyword: Gestational trophoblastic neoplasia, methotrexate, EMA/CO.

Sign in / Sign up

Export Citation Format

Share Document